Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long‑term outcomes after aflibercept vs laser for retinopathy of prematurity (extension of Study 20090)
jRCT2080225079Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of aflibercept in retinopathy of prematurity (ROP) (2 arms), sponsored by Bayer. Primary endpoint: Better binocular best‑corrected visual acuity (BCVA) at 5 years of age: aflibercept vs laser. Started Feb 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on jRCT2080225079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225079.